SCHEMBL10028945

SCHEMBL10028945

COc1cc(/C=C/C(=O)OC(C(=O)O)C(O)C(=O)O)ccc1O

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 1/20 0.75
EPHX2 P34913 1/20 0.64
HSD17B10 Q99714 3/20 0.62
TP53 P04637 2/20 0.62
ALOX15 P16050 2/20 0.62
TDP1 Q9NUW8 2/20 0.62
CA12 O43570 3/20 0.61
CA4 P22748 3/20 0.61
CA6 P23280 3/20 0.61
CA5A P35218 3/20 0.61
CA7 P43166 3/20 0.61
CA9 Q16790 3/20 0.61
CA14 Q9ULX7 3/20 0.61
CA5B Q9Y2D0 3/20 0.61
KDM4E B2RXH2 2/20 0.61
CA1 P00915 2/20 0.61
CA2 P00918 2/20 0.61
CA3 P07451 2/20 0.61
PKM P14618 2/20 0.61
SNCA P37840 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5597077 1.00 SRC (0.75) SRCEPHX2HSD17B10TP53ALOX15
SCHEMBL7627853 0.89 HSD17B10 (0.80) SRCEPHX2HSD17B10TP53ALOX15
Caffeoyltartaric Acid SCHEMBL30272738 0.86 SRC (1.00) SRCHSD17B10TP53ALOX15TDP1
Caffeoyltartaric Acid SCHEMBL962483 0.86 SRC (1.00) SRCHSD17B10TP53ALOX15TDP1
Caftaric Acid SCHEMBL16426394 0.86 SRC (1.00) SRCHSD17B10TP53ALOX15TDP1
Caffeoyltartaric Acid SCHEMBL24725181 0.86 SRC (1.00) SRCHSD17B10TP53ALOX15TDP1
Caffeoyltartaric Acid SCHEMBL826444 0.86 SRC (1.00) SRCHSD17B10TP53ALOX15TDP1
Caffeoyltartaric Acid SCHEMBL16426391 0.86 SRC (1.00) SRCHSD17B10TP53ALOX15TDP1
Caftaric Acid SCHEMBL29352215 0.86 SRC (1.00) SRCHSD17B10TP53ALOX15TDP1
SCHEMBL10000742 0.85 SRC (0.79) SRCEPHX2HSD17B10TP53ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260130395-A1 Water Dispersible Botanical Compositions AQUILA BLACK LTD (AU) 2026-05-14 US claimed
WO-2026087419-A1 PROCESS TO EFFICIENTLY RELEASE SUGARS AND/OR PHENOLIC COMPOUNDS FROM PLANT MATERIAL UNIVERSITEIT GENT (BE) 2026-04-30 WO claimed
EP-4323005-A1 DRUG DELIVERY VIA MONOACYLGLYCEROL AND FREE FATTY ACID-BASED COMPOSITIONS GlycosBio Inc. (US) 2024-02-21 EP claimed
EP-4323006-A1 MONOACYLGLYCEROL AND FREE FATTY ACID-BASED COMPOSITIONS, METHODS OF MANUFACTURING AND USE OF THE SAME GlycosBio Inc. (US) 2024-02-21 EP claimed
US-11732136-B2 Hydroxycinnamic acid-derived crosslinkers INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 2023-08-22 US claimed
WO-2023070172-A1 WATER DISPERSIBLE BOTANICAL COMPOSITIONS Aquila Black Limited (AU) 2023-05-04 WO claimed
US-11639432-B2 Hydroxycinnamic acid-derived crosslinking dimers INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 2023-05-02 US claimed
WO-2022221472-A1 MONOACYLGLYCEROL AND FREE FATTY ACID-BASED COMPOSITIONS, METHODS OF MANUFACTURING AND USE OF THE SAME GLYCOSBIO INC. (US) 2022-10-20 WO claimed
WO-2022221470-A1 DRUG DELIVERY VIA MONOACYLGLYCEROL AND FREE FATTY ACID-BASED COMPOSITIONS GLYCOSBIO INC. (US) 2022-10-20 WO claimed
WO-2022153155-A1 HYDROXYCINNAMIC ACID-DERIVED CROSSLINKING DIMERS INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 2022-07-21 WO claimed
WO-2022153156-A1 HYDROXYCINNAMIC ACID-DERIVED CROSSLINKERS INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 2022-07-21 WO claimed
US-20220220280-A1 HYDROXYCINNAMIC ACID-DERIVED CROSSLINKING DIMERS INTERNATIONAL BUSINESS MACHINES CORPORATION 2022-07-14 US claimed
US-20220220310-A1 HYDROXYCINNAMIC ACID-DERIVED CROSSLINKERS INTERNATIONAL BUSINESS MACHINES CORPORATION 2022-07-14 US claimed
EP-3941188-A1 PHYTOCOMPLEX AND EXTRACT OF A MERISTEMATIC CELL LINE SELECTED FROM ECHINACEA PURPUREA Aethera Biotech S.r.l. (IT) 2022-01-26 EP claimed
US-20260130395-A1 Water Dispersible Botanical Compositions AQUILA BLACK LTD (AU) 2026-05-14 US disclosed
WO-2026087419-A1 PROCESS TO EFFICIENTLY RELEASE SUGARS AND/OR PHENOLIC COMPOUNDS FROM PLANT MATERIAL UNIVERSITEIT GENT (BE) 2026-04-30 WO disclosed
EP-4649129-A1 PRESSURE ASSISTED DIAFILTRATION SEPARATION METHODS AND SYSTEMS Altr Fltr Inc. (US) 2025-11-19 EP disclosed
US-20120020926-A1 COMPOSITION COMPRISING CAFTARIC ACID AND/OR DERIVATIVES THEREOF NESTEC S.A. (CH) 2012-01-26 US disclosed
WO-2010086331-A2 COMPOSITION COMPRISING CAFTARIC ACID AND/OR DERIVATIVES THEREOF NESTEC S.A. (CH) 2010-08-05 WO disclosed
EP-2210505-A1 Composition comprising caftaric acid and/or derivatives thereof Nestec S.A. (CH) 2010-07-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260130395-A1 Water Dispersible Botanical Compositions TTPA, PNLIP, SRMS SRC 2209/4885EPHX2 1884/4885HSD17B10 2881/4885
US-20120020926-A1 COMPOSITION COMPRISING CAFTARIC ACID AND/OR DERIVATIVES THEREOF LCT, CA1, CA6 SRC 1402/4885EPHX2 1031/4885HSD17B10 368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.